WebDisclosure WebDisclosure
Basculer en Français
8714 Companies
152584 Keywords
88204 Articles
82003 Press releases
Headlines Articles Press releases POP Biotechnologies, Inc. Remove
  1. Home
  2. Companies
  3. POP Biotechnologies, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 09/27/2024 at 20:05, 8 months 15 days ago

    POP Biotechnologies Announces Positive Interim Results for COVID-19 Vaccine Trial

    COVID-19 Vaccine Phase 3 Trial Immunogenicity EuCorVac-19 POP BIO SNAP
  • BRIEF

    published on 09/27/2024 at 20:05, 8 months 15 days ago

    POP Biotechnologies annonce des résultats intermédiaires positifs pour l'essai d'un vaccin contre la COVID-19

    Vaccin Contre Le Covid-19 Essai De Phase 3 EuCorVac-19 POP BIOGRAPHIE INSTANTANÉE Immunogénicité
  • PRESS RELEASE

    published on 09/27/2024 at 20:00, 8 months 15 days ago

    POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

    POP Biotechnologies and EuBiologics announce positive findings of ECV-19 COVID-19 vaccine in Phase 3 trial in the Philippines, demonstrating safety, immunogenicity, and potential against Omicron variant
    COVID-19 Vaccine Phase 3 Trial POP Biotechnologies EuBiologics ECV-19
  • PRESS RELEASE

    published on 07/14/2023 at 18:00, 1 year 10 months ago

    POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

Accesswire
  • Published on 06/13/2025 at 17:16, 1 hour 54 minutes ago

    SouthGobi Announces Update on Mongolia Tax Audit

  • Published on 06/13/2025 at 16:00, 3 hours 10 minutes ago

    Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

  • Published on 06/13/2025 at 15:10, 4 hours ago

    SonicStrategy Applauds Upcoming Coinbase Integration of Sonic Blockchain and Its Native Token $S

  • Published on 06/13/2025 at 15:03, 4 hours 7 minutes ago

    Ur-Energy to Present June 17 at the Emerging Growth Conference

  • Published on 06/13/2025 at 14:00, 5 hours 10 minutes ago

    Interactive Strength Inc. (Nasdaq:TRNR) Updates FAQ's About $500M AI-focused $FET Treasury Strategy

View all ACCESSWIRE
EQS Group
  • Published on 06/13/2025 at 18:47, 22 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 06/13/2025 at 18:47, 22 minutes ago

    Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED

  • Published on 06/13/2025 at 18:42, 27 minutes ago

    Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED

  • Published on 06/13/2025 at 18:00, 1 hour 10 minutes ago

    BOA CONCEPT: Mise à disposition des documents préparatoires de l’Assemblée Générale du 26 juin 2025

  • Published on 06/13/2025 at 17:53, 1 hour 16 minutes ago

    Funding Circle Holdings plc: POS-Transaction in Own Shares

View all EQS
Les Echos
  • Published on 06/13/2025 at 18:07, 1 hour 2 minutes ago

    Déclaration des transactions sur actions propres réalisées du 2 juin au 6 juin 2025

  • Published on 06/13/2025 at 18:07, 1 hour 2 minutes ago

    Disclosure of trading in own shares between June 2nd and 6th, 2025

  • Published on 06/13/2025 at 17:45, 1 hour 25 minutes ago

    STEF : Droits de vote au 31-05-2025

  • Published on 06/13/2025 at 09:55, 9 hours 14 minutes ago

    Déclaration d'actions et de droits de vote au 31.05.2025

  • Published on 06/13/2025 at 09:33, 9 hours 37 minutes ago

    Combined General Meeting, June 12, 2025

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy